GBI Research, the leading business intelligence provider, has released its latest report, “Drug Discovery in India and China – Gaining Momentum with Increasing Pressure on Cost Cutting.” It provides key data, information and analysis of the major trends and issues affecting the drug discovery market in India and China. The report provides a comprehensive insight into the drug discovery process and the model followed by the companies providing such services. The report also provides a detailed analysis of the factors that are driving the drug discovery market, a key segment of the pharmaceutical and healthcare industry, in India and China. The report talks about the key regulations, especially with respect to intellectual property rights protection, and how these regulations have benefited drug discovery companies in these two nations. The study analyses key partnerships between the local companies in the two countries and their western counterparts and the key trends emerging out of such partnerships. It also provides an insight into the government support initiatives in these countries to encourage the drug discovery research. This research provides a comparative analysis of the two countries and the major differences between India and China when it comes to drug discovery.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
  • Study of major discovery research services including medicinal chemistry, Drug Metabolism and Pharmacokinetics (DMPK), pharmacology and toxicology offered by the Indian and the Chinese drug discovery companies
  • Analysis of major therapeutic areas under drug discovery research such as oncology, inflammatory diseases and metabolic diseases
  • Study of key Indian and Chinese drug discovery players such as Aurigene, Syngene, WuXi and Shanghai ChemPartner, and their deals/partnerships with western pharma companies
  • Analysis of key intellectual property regulations and government support in India and China affecting the drug discovery market
  • Analysis of the key drivers that are fueling the growth of the drug discovery market in India and China and future outlook of the drug discovery market in India and China
Reasons to buy

The report will enhance your decision making and will enable you to:
  • Optimize your discovery research outsourcing through identification of major service capabilities of the Indian and Chinese drug discovery companies
  • Develop market entry and market expansion strategies by identifying the key drivers and restraints in the Indian and Chinese drug discovery market
  • Identify the key therapeutic areas in which Indian and Chinese drug discovery companies have major capabilities
  • Build a strong presence in the Indian and Chinese drug discovery market through identification of key local players for partnerships and their competencies
  • Compare both the countries to identify the geography that could provide maximum capability improvement to your discovery research
  • Plan better strategies to protect your intellectual property in these countries
  • Enhance and frame better marketing strategies through an understanding of the regulatory environment in these countries

About Us
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004

Original Source: Drug Discovery Market
Buy Now: Market Research

Subscribe via email

Enter your email address:

Delivered by FeedBurner

FeedBurner FeedCount

Blog Archive